Clinical Trial Update: Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer

View source ↗

Summary

This clinical trial update reports on real-world experience with lutetium vipivotide tetraxetan in metastatic castration-resistant prostate cancer. The study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Lutetium vipivotide tetraxetan (lutetium-177 vipivotide tetraxetan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Castration Resistant Prostate Cancer | Status: RECRUITING